These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34336705)

  • 41. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma.
    Singh K; Hotchkiss KM; Patel KK; Wilkinson DS; Mohan AA; Cook SL; Sampson JH
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.
    Garzon-Muvdi T; Theodros D; Luksik AS; Maxwell R; Kim E; Jackson CM; Belcaid Z; Ganguly S; Tyler B; Brem H; Pardoll DM; Lim M
    Oncotarget; 2018 Apr; 9(29):20681-20697. PubMed ID: 29755681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
    Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of infantile fibrosarcoma reveals extensive T-cell responses within tumors: Implications for immunotherapy.
    Zhu H; Gu S; Yin M; Shi M; Xin C; Zhu J; Wang J; Huang S; Xie C; Ma J; Pan C; Tang J; Xu M; Bai XF
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 49. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles.
    Wang T; Zhang H; Han Y; Zheng Q; Liu H; Han M; Li Z
    Adv Sci (Weinh); 2023 Mar; 10(9):e2204961. PubMed ID: 36698265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.
    De Waele J; Marcq E; Van Audenaerde JR; Van Loenhout J; Deben C; Zwaenepoel K; Van de Kelft E; Van der Planken D; Menovsky T; Van den Bergh JM; Willemen Y; Pauwels P; Berneman ZN; Lardon F; Peeters M; Wouters A; Smits EL
    Oncoimmunology; 2018; 7(3):e1407899. PubMed ID: 29399410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma.
    Frederico SC; Hancock JC; Brettschneider EES; Ratnam NM; Gilbert MR; Terabe M
    Front Oncol; 2021; 11():672508. PubMed ID: 34041034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept.
    Cohen-Inbar O; Xu Z; Sheehan JP
    J Ther Ultrasound; 2016; 4():2. PubMed ID: 26807257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.
    Venetz D; Ponzoni M; Schiraldi M; Ferreri AJ; Bertoni F; Doglioni C; Uguccioni M
    Int J Cancer; 2010 Nov; 127(10):2300-12. PubMed ID: 20872671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.